. Author manuscript; available in PMC: 2022 Oct 14.

Published in final edited form as: FASEB J. 2022 Oct;36(10):e22514. doi: 10.1096/fj.202200765R

Table 2:

Human AML cell lines used in this study

Cell line	Source	Mutations
OCI-AML-2	peripheral blood of a 65 year-old-male with acute myeloid leukemia	DNMT3A R635W (MLL-MLLT4; MLL-AF6) gene fusion
MOLM-14	peripheral blood of a 20 year-old-male with acute myeloid leukemia	FLT3-ITD (MLL-MLLT3; MLL-AF9) fusion
HL-60	Peripheral blood of the 36 year old-female with acute promyelocytic leukemia	N-RAS Q61L, amplified c-MYC
MV4-11	Blasts of a 10-year-old male with biphenotypic B-myelomonocytic leukemia ( AML FAB M5)	FLT3-ITD, MLL-AFF1 gene fusion